false

Fred Snikeris

Fred Snikeris, PhD is an established biometrics executive with extensive Pharmaceutical R&D and CRO experience. He has built self-sustaining global multi-site biostatistics departments in support of late phase and early phase clinical development and preclinical research efforts.

• Read: Phase I Clinical Trial Designs: Modified Toxicity Probability Interval

  Clinical Trials - Early Phase Research - Oncology

  Phase I Clinical Trial Designs: Modified Toxicity Probability Interval

  Mar 28, ‘23 | 3 min read

  • 

    Fred Snikeris

  Discover

Loading...

You've reach the end Back to top